Avancée majeure pour EG 427 avec le premier patient traité par EG110A, la première thérapie génique à base d’un vecteur herpétique non réplicatif pour le traitement de la vessie neurogène
February 27, 2025 02:00 ET
|
EG 427
Premier patient traité avec succès dans l’étude clinique EG110A menée dans quatre institutions médicales de premier plan aux États-UnisÉtude de phase 1b/2a visant à recruter 16 patients atteints...
Significant milestone reached for EG 427 with first patient treated with EG110A, first non-replicative herpes vector based genetic medicine for the treatment of neurogenic bladder
February 27, 2025 02:00 ET
|
EG 427
First patient now successfully dosed in the EG110A clinical study being conducted at four leading US institutionsPhase 1b/2a study to recruit 16 patients with neurogenic detrusor overactivity...
ONWARD Medical's ARC-EX System Now Available on US Veterans Affairs Online Procurement Platforms
January 29, 2025 01:30 ET
|
ONWARD Medical NV
ONWARD Medical's ARC-EX System Now Available on US Veterans Affairs Online Procurement Platforms
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 27, 2024 07:01 ET
|
NurExone Biologic Inc
NurExone Reports Third Quarter 2024 Financial Results
and Provides Corporate Update
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
November 13, 2024 16:14 ET
|
NurExone Biologic Inc
European Medicines Agency Awards Orphan Status to NurExone's ExoPTEN for Spinal Cord Injury, Paving the Way to European Market Entry
Allsup Employment Services Bridges The Employment Gap For Spinal Cord Injury Survivors
October 09, 2024 12:15 ET
|
Allsup
Belleville, Illinois, Oct. 09, 2024 (GLOBE NEWSWIRE) -- As the economy fuels job opportunities, Allsup Employment Services (AES) , a Social Security-authorized Employment Network (EN), reaffirms its...
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
September 06, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
August 23, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone Biologic to present its innovative ExoPTEN therapy at key September conferences in Boston and New York, showcasing its leadership in regenerative
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
August 09, 2024 16:04 ET
|
NurExone Biologic Inc
NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
June 11, 2024 08:44 ET
|
NurExone Biologic Inc
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application